GlassScriptPhysician profile
Matti W Palo
NPI 1013949619
$9,687.09
in general payments reported to CMS, 2019-2025
35 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $358 · 2021: $589 · 2022: $1,366 · 2023: $1,326 · 2024: $2,002 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Travel and Lodging: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.40 |
| Travel and Lodging | $1,531.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,549.08 | 2019-2025 | Mako, Reunion, Aequalis Perform |
| Medacta USA, INC. | $1,460.61 | 2023-2024 | Reverse Shoulder |
| Zimmer Biomet Holdings, INC. | $871.44 | 2025 | Oxford |
| Pacira Pharmaceuticals Incorporated | $657.87 | 2020-2022 | |
| Depuy Synthes Sales INC. | $410.53 | 2019-2022 | |
| Amgen INC. | $298.23 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Radius Health, INC. | $263.99 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $125.37 | 2019-2022 | |
| Vericel Corporation | $114.20 | 2020-2023 | Maci |
| Novo Nordisk INC | $109.86 | 2021-2022 | |
| Pacira Therapeutics, INC. | $99.31 | 2019-2021 | |
| Abbvie INC. | $78.16 | 2019-2025 | |
| Bioventus LLC | $75.34 | 2022-2024 | Exogen Ultrasound Bone Healing System, Durolane |
| Vertex Pharmaceuticals Incorporated | $52.33 | 2025 | |
| Biocomposites INC | $50.00 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.79 | 2022-2023 | Freestyle Libre |
| Smith+Nephew, INC. | $36.94 | 2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Alnylam Pharmaceuticals INC. | $36.23 | 2021 | |
| Endo Pharmaceuticals INC. | $36.08 | 2019-2023 | Xiaflex |
| Boston Scientific Corporation | $31.40 | 2021-2023 | |
| Esaote North America, INC. | $30.02 | 2025 | |
| Innovation Technologies INC | $26.94 | 2024 | Irrisept |
| Relievant Medsystems, INC. | $25.13 | 2023 | Intracept |
| Nalu Medical, INC. | $23.59 | 2025 | Nalu Neurostimulation System |
| Organogenesis INC. | $22.18 | 2025 | Simpligraft |
| Fidia Pharma USA INC. | $22.14 | 2025 | Hymovis, Triluron |
| Alvogen INC | $21.38 | 2025 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2019 | |
| Sanofi Pasteur INC. | $15.85 | 2019 | |
| Spinal Simplicity, LLC | $15.82 | 2023 | Ha Minuteman G3-R |
| Nevro Corp. | $14.98 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.66 | 2023 | Linzess |
| Sonex Health, INC. | $14.00 | 2024 | Sx-One Microknife |
| Amarin Pharma, INC. | $13.52 | 2019 | |
| Avanos Medical | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matti Palo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.